Cardiovascular disease in HIV infection

American Heart Journal

Volumn 151, Issue 6, 2006, Pages 1147-1155

  Sudano, Isabella ^a   Spieker, Lukas E ^a   Noll, Georg ^a   Corti, Roberto ^a   Weber, Rainer ^a   Lüscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DIGOXIN; DIHYDROPYRIDINE; DOXORUBICIN; FLUINDOSTATIN; FOSCARNET; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PENTAMIDINE; PRAVASTATIN; PROTEINASE INHIBITOR; PYRIMETHAMINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZIDOVUDINE;

ATHEROSCLEROSIS; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DYSLIPIDEMIA; ENDOCARDITIS; HEART ANEURYSM; HEART ARRHYTHMIA; HEART DISEASE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE CONTRACTION; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEART TAMPONADE; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INSULIN RESISTANCE; INTRAVENOUS DRUG ABUSE; LIPODYSTROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; MYOCARDITIS; NEOPLASM; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PERICARDIAL EFFUSION; PERICARDITIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QT PROLONGATION; RESTENOSIS; REVIEW; RISK FACTOR; SMOKING; SURVIVAL; TORSADE DES POINTES; TOXOPLASMOSIS; VASCULAR DISEASE; WASTING SYNDROME;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HEART DISEASES; HIV INFECTIONS; HUMANS;

EID: 33746233466     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.07.030     Document Type: Review

References (64)

1. d'Arminio Monforte A., Sabin C.A., Phillips A., et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 165 (2005) 416-423
2. Fauci A.S. The AIDS epidemic-considerations for the 21st century. N Engl J Med 341 (1999) 1046-1050
3. Joint United Nations Programme on HIV/AIDS (UNAIDS) WHO. AIDS epidemic update: December 2004 (2004), UNAIDS 2004, Geneva. http://www.unaids.org Available at
4. Peterman T.A., Lindsey C.A., and Selik R.M. This place is killing me: a comparison of counties where the incidence rates of AIDS increased the most and the least. J Infect Dis 191 Suppl 1 (2005) S123-S126
5. Pugliese A., Isnardi D., Saini A., et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 40 (2000) 282-284
6. Moreno R., Villacastin J.P., Bueno H., et al. Clinical and echocardiographic findings in HIV patients with pericardial effusion. Cardiology 88 (1997) 397-400
7. Lepori M., Tinguely F., Erard V., et al. Pericardial involvement in an HIV-infected patient. Schweiz Med Wochenschr 129 (1999) 736-740
8. Trautner B.W., and Darouiche R.O. Tuberculous pericarditis: optimal diagnosis and management. Clin Infect Dis 33 (2001) 954-961
9. Hofman P., Drici M.D., Gibelin P., et al. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J 70 (1993) 376-381
10. Mosterd A., Hoes A.W., de Bruyne M.C., et al. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam Study. Eur Heart J 20 (1999) 447-455
11. Frerichs F.C., Dingemans K.P., and Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med 347 (2002) 1895-1896
12. McAllister Jr. H.A., Hall R.J., and Cooley D.A. Tumors of the heart and pericardium. Curr Probl Cardiol 24 (1999) 57-116
13. Stotka J.L., Good C.B., Downer W.R., et al. Pericardial effusion and tamponade due to Kaposi's sarcoma in acquired immunodeficiency syndrome. Chest 95 (1989) 1359-1361
14. Kelsey R.C., Saker A., and Morgan M. Cardiac lymphoma in a patient with AIDS. Ann Intern Med 115 (1991) 370-371
15. Nishikawa Y., Akaishi M., Handa S., et al. A case of malignant lymphoma simulating acute myocardial infarction. Cardiology 78 (1991) 357-362
16. Miro JM, del Rio A, Mestres CA. Infective endocarditis and cardiac surgery in intravenous drug abusers and HIV-1 infected patients. Cardiol Clin 2003;21:167-84, v-vi.
17. Pulvirenti J.J., Kerns E., Benson C., et al. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. Clin Infect Dis 22 (1996) 40-45
18. Le Houssine P., Karmochkine M., Ledru F., et al. Primary pulmonary hypertension in human immunodeficiency virus infection. Study of 9 cases and review of the literature. Rev Med Interne 22 (2001) 1196-1203
19. Mesa R.A., Edell E.S., Dunn W.F., et al. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 73 (1998) 37-45
20. Pellicelli A.M., Palmieri F., Cicalini S., et al. Pathogenesis of HIV-related pulmonary hypertension. Ann N Y Acad Sci 946 (2001) 82-94
21. Barst R.J., and Loyd J.E. Genetics and immunogenetic aspects of primary pulmonary hypertension. Chest 114 (1998) 231S-236S
22. Petureau F., Escamilla R., Hermant C., et al. Pulmonary artery hypertension in HIV seropositive drug addicts. Apropos of 10 cases. Rev Mal Respir 15 (1998) 97-102
23. Klings E.S., and Farber H.W. Current management of primary pulmonary hypertension. Drugs 61 (2001) 1945-1956
24. Aguilar R.V., and Farber H.W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 162 (2000) 1846-1850
25. Speich R., Jenni R., Opravil M., et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 131 (2001) 663-665
26. Pellicelli A.M., Palmieri F., D'Ambrosio C., et al. Role of human immunodeficiency virus in primary pulmonary hypertension-case reports. Angiology 49 (1998) 1005-1011
27. Nair R., Robbs J.V., Naidoo N.G., et al. Clinical profile of HIV-related aneurysms. Eur J Vasc Endovasc Surg 20 (2000) 235-240
28. Chetty R. Vasculitides associated with HIV infection. J Clin Pathol 54 (2001) 275-278
29. Vittecoq D., Escaut L., Chironi G., et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 17 Suppl 1 (2003) S70-S76
30. Bozzette S.A., Ake C.F., Tam H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348 (2003) 702-710
31. Monsuez J.J., Gallet B., Escaut L., et al. Clinical outcome after coronary events in patients treated with HIV-protease inhibitors. Eur Heart J 21 (2000) 2079-2080
32. Holmberg S.D., Moorman A.C., Williamson J.M., et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360 (2002) 1747-1748
33. Friis-Moller N., Weber R., Reiss P., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1193
34. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
35. Stein J.H., Klein M.A., Bellehumeur J.L., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104 (2001) 257-262
36. Behrens G.M., Boerner A.R., Weber K., et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 110 (2002) 1319-1327
37. Dressman J., Kincer J., Matveev S.V., et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111 (2003) 389-397
38. Chironi G., Escaut L., Gariepy J., et al. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr 32 (2003) 490-493
39. Bernasconi E., Boubaker K., Junghans C., et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 31 (2002) 50-55
40. Carter V.M., Hoy J.F., Bailey M., et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2 (2001) 174-180
41. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 (1999) 2093-2099
42. Nicholas P.K., Kirksey K.M., Corless I.B., et al. Lipodystrophy and quality of life in HIV: symptom management issues. Appl Nurs Res 18 (2005) 55-58
43. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
44. Tershakovec A.M., Frank I., and Rader D. HIV-related lipodystrophy and related factors. Atherosclerosis 174 (2004) 1-10
45. Ambrose J.A., Gould R.B., Kurian D.C., et al. Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection. Am J Cardiol 92 (2003) 301-303
46. Hsue P.Y., Giri K., Erickson S., et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109 (2004) 313-319
47. Grover S.A., Coupal L., Gilmore N., et al. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy. Am J Cardiol 95 (2005) 586-591
48. Dube M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37 (2003) 613-627
49. Calza L., Manfredi R., and Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 53 (2004) 10-14
50. Hulgan T., Sterling T.R., Daugherty J., et al. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 38 (2005) 277-282
51. Miller J., Brown D., Amin J., et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16 (2002) 2195-2200
52. Carr A., Hudson J., Chuah J., et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15 (2001) 1811-1822
53. Martinez E., Arnaiz J.A., Podzamczer D., et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 349 (2003) 1036-1046
54. Carr A., Workman C., Smith D.E., et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288 (2002) 207-215
55. Cofrancesco Jr J, Brown T, Martins CR. Management options for facial lipoatrophy. AIDS Read 2004;14:639-40, 645-50.
56. Mestres C.A., Chuquiure J.E., Claramonte X., et al. Long-term results after cardiac surgery in patients infected with the human immunodeficiency virus type-1 (HIV-1). Eur J Cardiothorac Surg 23 (2003) 1007-1016 [discussion 1016]
57. Chong T., Alejo D.E., Greene P.S., et al. Cardiac valve replacement in human immunodeficiency virus-infected patients. Ann Thorac Surg 76 (2003) 478-480 [discussion 480-1]
58. Halpern S.D., Ubel P.A., and Caplan A.L. Solid organ transplantation in HIV-infected patients. N Engl J Med 347 (2002) 284-287
59. Calabrese L.H., Albrecht M., Young J., et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 348 (2003) 2323-2328
60. Roland M.E., and Havlir D.V. Responding to organ failure in HIV-infected patients. N Engl J Med 348 (2003) 2279-2280
61. Krishnan A., Molina A., Zaia J., et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 98 (2001) 3857-3859
62. Sekigawa I., Koshino K., Hishikawa T., et al. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. J Clin Immunol 15 (1995) 312-317
63. Jain A.K., Venkataramanan R., Shapiro R., et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc 34 (2002) 1540-1541
64. Seminari E., Pan A., Voltini G., et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162 (2002) 433-438